Clinical Trial Detail

NCT ID NCT02834247
Title A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

head and neck squamous cell carcinoma

triple-receptor negative breast cancer

lung non-small cell carcinoma

Advanced Solid Tumor

Therapies

Mivavotinib + Nivolumab

Age Groups: senior adult

No variant requirements are available.